Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 450 000 KRW 3.81% Market Closed
Market Cap: 5.8T KRW

Hanmi Pharm Co Ltd's latest stock split occurred on Dec 27, 2023

The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.

Before the split, Hanmi Pharm Co Ltd traded at 344499.9375 per share. Afterward, the share price was about 339693.1408.

The adjusted shares began trading on Dec 27, 2023. This was Hanmi Pharm Co Ltd's 15th stock split, following the previous one in Dec 28, 2022.

Last Splits:
Dec 27, 2023
1-for-1
Dec 28, 2022
1-for-1
Dec 29, 2021
1-for-1
Dec 29, 2020
1-for-1
Dec 27, 2019
1-for-1
Pre-Split Price
336 940.664 344 499.9375
Post-Split Price
339 693.1408
Before
After
Last Splits:
Dec 27, 2023
1-for-1
Dec 28, 2022
1-for-1
Dec 29, 2021
1-for-1
Dec 29, 2020
1-for-1
Dec 27, 2019
1-for-1

Hanmi Pharm Co Ltd
Stock Splits History

Hanmi Pharm Co Ltd Stock Splits Timeline
Dec 27, 2023
Dec 27, 2023
Split 1-for-1
/1
Pre-Split Price
336 940.664 344 499.9375
Post-Split Price
339 693.1408
Before
After
Dec 28, 2022
Dec 28, 2022
Split 1-for-1
/1
Pre-Split Price
293 886.9214 306 999.8886
Post-Split Price
293 417.1239
Before
After
Dec 29, 2021
Dec 29, 2021
Split 1-for-1
/1
Pre-Split Price
270 283.193 288 499.8431
Post-Split Price
263 732.4001
Before
After
Dec 29, 2020
Dec 29, 2020
Split 1-for-1
/1
Pre-Split Price
302 632.3266 329 999.8409
Post-Split Price
326 494.6023
Before
After
Dec 27, 2019
Dec 27, 2019
Split 1-for-1
/1
Pre-Split Price
275 120.3139 306 499.8715
Post-Split Price
264 115.485
Before
After
Dec 27, 2018
Dec 27, 2018
Split 1-for-1
/1
Pre-Split Price
397 319.7652 451 999.8386
Post-Split Price
404 377.4923
Before
After
Dec 27, 2017
Dec 27, 2017
Split 1-for-1
/1
Pre-Split Price
495 089.7762 574 999.6903
Post-Split Price
510 714.123
Before
After
Feb 15, 2017
Feb 15, 2017
Split 1-for-1
/1
Pre-Split Price
254 284.1093 315 999.6864
Post-Split Price
264 765.402
Before
After
Dec 29, 2015
Dec 29, 2015
Split 1-for-1
/1
Pre-Split Price
515 163.4796 654 999.2313
Post-Split Price
592 256.6596
Before
After
Dec 29, 2014
Dec 29, 2014
Split 1-for-1
/1
Pre-Split Price
76 403.749 101 999.8869
Post-Split Price
78 650.9129
Before
After
Feb 10, 2014
Feb 10, 2014
Split 1-for-1
/1
Pre-Split Price
103 441.1236 144 999.8488
Post-Split Price
103 369.7781
Before
After
Dec 16, 2013
Dec 16, 2013
Split 540-for-529
x1.0207939508507
Pre-Split Price
85 959.2249 120 494.3853
Post-Split Price
82 396.2053
Before
After
Dec 27, 2012
Dec 27, 2012
Split 1-for-1
/1
Pre-Split Price
N/A
Post-Split Price
98 888.0515
Before
After
Dec 28, 2011
Dec 28, 2011
Split 1-for-1
/1
Pre-Split Price
N/A
Post-Split Price
98 888.0515
Before
After
Dec 29, 2010
Dec 29, 2010
Split 1-for-1
/1
Pre-Split Price
N/A
Post-Split Price
98 888.0515
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.78 45.78 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
62.79 62.79 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Hanmi Pharm Co Ltd
Glance View

Market Cap
5.7T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Intrinsic Value
348 105.54 KRW
Overvaluation 23%
Intrinsic Value
Price
Back to Top